Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P35221
UPID:
CTNA1_HUMAN
Alternative names:
Alpha E-catenin; Cadherin-associated protein; Renal carcinoma antigen NY-REN-13
Alternative UPACC:
P35221; Q12795; Q8N1C0
Background:
Catenin alpha-1, also known as Alpha E-catenin, plays a pivotal role in cell adhesion by associating with the cytoplasmic domain of cadherins to form a complex linked to the actin filament network. This interaction is crucial for the cell-adhesion properties of cadherins. Catenin alpha-1 is involved in the regulation of several key pathways, including those of WWTR1/TAZ, YAP1, and TGFB1-dependent SMAD2 and SMAD3 nuclear accumulation, highlighting its importance in cell differentiation.
Therapeutic significance:
Catenin alpha-1's involvement in Macular dystrophy, patterned, 2, a retinal disorder, underscores its potential as a target for therapeutic intervention. Understanding the role of Catenin alpha-1 could open doors to potential therapeutic strategies.